Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IOVA)

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

GlobeNewswire February 27, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 21, 2025

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

GlobeNewswire February 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 12, 2025

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

GlobeNewswire February 10, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 17, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 20, 2024

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

GlobeNewswire November 26, 2024

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

GlobeNewswire November 7, 2024
View More News ››

Opinion & Analysis (NDAQ:IOVA)

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Streetwise Reports November 12, 2019

Preliminary Phase 2 clinical data provides 'first spark to game-changing thesis'

Streetwise Reports January 31, 2018

Cell therapy for melanoma impresses in Phase 2

The Life Sciences Report August 10, 2017
View More Opinion ››

Bullboard Posts (NDAQ:IOVA)

Where Will Iovance Biotherapeutics Be in 5 Years?

JUST IN: $IOVA Where Will Iovance Biotherapeutics Be in 5 Years?2025-01-29 08:30:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) , a small...
whytestocks - January 29, 2025

Meet the Growth Stock That Could Soar 280%, According to Wal

Just In: $IOVA Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts2025-01-27 04:31:00 ET If you're looking...
whytestocks - January 27, 2025

3 Mid-Cap Stocks That Could Take Off in 2025

Breaking News: $IOVA 3 Mid-Cap Stocks That Could Take Off in 20252025-01-09 04:20:00 ET Some of the best possible returns for investors...
whytestocks - January 9, 2025

2 Innovative Stocks That Could Deliver Outsize Returns

JUST IN: $IOVA 2 Innovative Stocks That Could Deliver Outsize Returns2024-11-22 10:00:00 ET Many of Wall Street's largest and most...
whytestocks - November 22, 2024

Neutral Recommendation Issued On IOVA By Piper Sandler

BREAKING NEWS: $IOVA Neutral Recommendation Issued On IOVA By Piper Sandler2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL...
whytestocks - July 29, 2024

IOVA Price Target Alert: $10.00. Issued by Piper Sandler

BREAKING NEWS: $IOVA IOVA Price Target Alert: $10.00. Issued by Piper Sandler2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler...
whytestocks - July 29, 2024
View more Bullboard ››

Geodrill Limited

Geodrill Limited

Geodrill Limited is an Isle of Man-based exploration drilling company with a fleet of 76 drill rigs operating in Africa and ...
View More »